Dr. Monk on Bevacizumab in Cervical Cancer

Bradley J. Monk, MD
Published Online: Tuesday, Dec 31, 2013

Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.
 
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses the role of bevacizumab in the treatment of metastatic cervical cancer.

Monk says the recently completed phase III GOG 240 study looked at the addition of bevacizumab to standard chemotherapy for the treatment of metastatic cervical cancer. The study showed that adding bevacizumab improved overall survival by nearly 4 months and improved response rate to about 50%.

Monk says this is a remarkable achievement, since metastatic cervical cancer is resistant to chemotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations®: Identifying Best Practices of the Multidisciplinary Team in CINV ManagementJun 28, 20172.0
Community Practice Connections™: A Team-Based Approach to Enhanced Recovery: Controlling Postsurgical Pain in Breast Cancer PatientsJun 29, 20172.0
Publication Bottom Border
Border Publication
$emailPop$